The approval of the anti-EGFR mAbs—cetuximab and panitumumab—for the treatment of mCRC and, in recent years, necitumumab for lung cancer [5,7,27,28,29], emphasises the importance of EGFR as a therapeutic target in human cancers. This evidence concerns the gene EGFR and lung carcinoma.